Skip to main content
NIH funding notice RFA-CA-14-002

SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics toward Commercialization

Closed on April 21, 2014.

Posted
February 12, 2014
Close date
April 21, 2014
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

Competing awards, new and renewals, since FY2014, under this notice and the notices it replaced.

Past awards
2
2 renewals
Median first-year cost
$996,426
$1,992,851 in all
Institutions
2
2 contact PIs

Awards by fiscal year

Fiscal years 2014 to 2026.

Most frequent institutions

  1. HYPER TECH RESEARCH, INC.1
  2. J AND J SOLUTIONS, INC.1

Most frequent study sections

  1. Special Emphasis Panel (ZCA1 TCRB-9 (A1))2
2 awards under RFA-CA-14-002 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
FY2014Helium Free MRI Image Guided Radiation Therapy (IGRT) System for ViewRay Inc2R44CA144415-05Tomsic, Michael JHYPER TECH RESEARCH, INC., OHFirst-year cost $1,000,000Study section ZCA1
FY2014Innovative Device to Improve Safety of Preparing and Administering Chemotherapy2R44CA153636-04Bartel, SylviaSunkara, PrasadJ AND J SOLUTIONS, INC., IAFirst-year cost $992,851Study section ZCA1
Newest fiscal year first, then first-year cost.

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-12-0.3.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for departments

Open NIH notices that fit your faculty

See which open NIH funding notices fit each faculty member's CV, why each fits, and who won before.

RFA-CA-14-002: SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics toward Commercialization | ScienceDex | ConductScience